Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-case post-marketing surveillance of Opdivo in unresectable or metastatic renal cell cancer
jRCT1080224010Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in renal cell carcinoma (RCC), sponsored by Ono Pharmaceutical. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT1080224010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224010.